P176 Patient reported outcome measures derived from the Crohn's Disease Activity Index: Correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds (2014)

of life, little is known about their satisfaction with clinical management, or with associated drug treatment. Knowing the perception and satisfaction that patients have about the management of their disease, it will allow designing strategies aimed to improve patients’ quality of life and promoting adherence and treatment effectiveness. The aim of this study is to understand perceptions, attitudes, experiences, and satisfaction with clinical management of UC patients, particularly in aspects related to treatment. Methods: A discussion group was performed with eight UC patients in remission who had not received biologics or corticosteroids during the previous year. The heterogeneity was ensured by selecting different UC profiles using the following variables: severity, time since onset, follow-up level of care, currently on treatment, managed by a UC care unit, patients belonging to any patient association and gender. Following qualitative methodology a descriptive-interpretative content analysis was performed to detect emerging categories, building an explanatory framework. Results: The most frequent mentions are related to diagnostic process, follow-up and treatment. Diagnostic delay was detected due to lack of clinical suspicion from primary care (PC) and delayed diagnostic tests. Patients prefer to receive care on demand, channeled through remote care, which helps to resolve questions about UC, issues with treatment, or when a relapse occurs, and minimizes visits to the hospital. Patients with moderate UC diagnosis perceive some training lacks in PC physicians about management of symptoms, although, in general, they declare their satisfaction with follow-up both in PC and specialist care. When forced to go to the emergency room, they are quite dissatisfied with management, due to the delay in providing symptoms resolution, mainly related to inadequate knowledge of UC management. To avoid this, patients suggest the possibility of receiving care on demand from a specialist in UC. In relation to treatment, patients expect it to be effective, reducing symptoms. Secondly, treatment should be safe, minimizing short and long-term side effects. Regarding to treatment characteristics that patients would like to improve, they mention a reduction in the number of doses and tablets per day, and an increased number of tablets per box. Conclusions: These results suggest the importance of developing strategies to facilitate care on demand, remote care, and to investigate on effective and safe treatments to improve patients’ quality of life. P176 Patient reported outcome measures derived from the Crohn’s Disease Activity Index: Correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds R. Khanna1, G. D’Haens1,2, B.G. Feagan1,3, W.J. Sandborn1,4, M.K. Vandervoort1, G. Zou1, R.L. Rolleri5, E. Bortey5, B.G. Levesque1,4 *. 1Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 2University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 3Western University, Department of Epidemiology and Biostatistics, Department of Medicine, London Ontario, Canada, 4University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 5Salix Pharmaceuticals Inc., Clinical Development, Raleigh North Carolina, United States